October 2006
 
Volume 1, Issue 1

The Metabolic Syndrome Institute Literature Watch features the latest articles on the metabolic syndrome. Click on the links below to view the abstracts for each article.

Adiponectin

  1. Araki S, Dobashi K, Kubo K, Asayama K, Shirahata A.
    High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity.
    J Clin Endocrinol Metab. 2006 Sep 19; [Epub ahead of print]

  2. Behre CJ, Brohall G, Hulthe J, Wikstrand J, Fagerberg B.
    Are serum adiponectin concentrations in a population sample of 64-year-old Caucasian women with varying glucose tolerance associated with ultrasound-assessed atherosclerosis?
    J Intern Med. 2006 Sep;260(3):238-44.

  3. Bronsky J, Karpisek M, Bronska E, Pechova M, Jancikova B, Kotolova H, Stejskal D, Prusa R, Nevoral J.
    Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk.
    Clin Chem. 2006 Sep;52(9):1763-70. Epub 2006 Jul 27.

  4. Esposito K, Giugliano G, Scuderi N, Giugliano D.
    Role of adipokines in the obesity-inflammation relationship: the effect of fat removal.
    Plast Reconstr Surg. 2006 Sep 15;118(4):1048-57; discussion 1058-9.

  5. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R; for the Multiple Risk Factor Intervention Trial Research Group.
    Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.
    Atherosclerosis. 2006 Sep 29; [Epub ahead of print]

  6. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K,
    Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T.
    Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.
    Kidney Int. 2006 Sep 20; [Epub ahead of print]

  7. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Zhang H, Sugiura K, Kondo T, Murohara T, Toyoshima H.
    Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men.
    Atherosclerosis. 2006 Sep;188(1):184-9. Epub 2005 Dec 1.

  8. Nishimura A, Sawai T.
    Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer.
    Clin Chim Acta. 2006 Sep;371(1-2):163-8. Epub 2006 May 18.

  9. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Matsui K, Sakamoto T, Yoshimura M, Kimura K, Umemura S, Ogawa H.
    Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease.
    J Am Coll Cardiol. 2006 Sep 19;48(6):1155-62. Epub 2006 Aug 28.

  10. Sieminska L, Wojciechowska C, Foltyn W, Kajdaniuk D, Kos-Kudla B, Marek B, Nasiek M, Nowak M, Strzelczyk J, Zemczak A.
    The relation of serum adiponectin and leptin levels to metabolic syndrome in women before and after the menopause.
    Endokrynol Pol. 2006 Sep-Oct;57(1):15-24.

  11. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ.
    The Evolving Role of Leptin and Adiponectin in Chronic Liver Diseases.
    Am J Gastroenterol. 2006 Sep 4; [Epub ahead of print]

back to top

Cardiovascular disease

  1. Aronson D, Roterman I, Yigla M, Kerner A, Avizohar O, Sella R, Bartha P, Levy Y, Markiewicz W.
    Inverse Association between Pulmonary Function and C-Reactive Protein in Apparently Healthy Subjects.
    Am J Respir Crit Care Med. 2006 Sep 15;174(6):626-32. Epub 2006 Jun 15.

  2. Brown WV.
    Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease.
    Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):492-3. No abstract available.

  3. Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, Shofer JB, Heckbert SR, Boyko EJ, Fujimoto WY, Kahn SE.
    Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes.
    Diabetes Care. 2006 Sep;29(9):2078-83.

  4. Kawamoto R, Tomita H, Oka Y, Ohtsuka N.
    Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis.
    Intern Med. 2006 Sep;45(9):605-14. Epub 2006 Jun 1.

  5. Leclercq IA, Vansteenberghe M, Lebrun VB, Vanhul NK, Abarca-Quinones J, Sempoux CL, Picard C, Starkel P, Horsmans YL.
    Defective hepatic regeneration after partial hepatectomy in leptin-deficient mice is not rescued by exogenous leptin.
    Lab Invest. 2006 Sep 18; [Epub ahead of print]

  6. Lowe GD, Pepys MB.
    C-reactive protein and cardiovascular disease: weighing the evidence.
    Curr Atheroscler Rep. 2006 Sep;8(5):421-8.

  7. Ma J, Lee KV, Berra K, Stafford RS.
    Implementation of Case Management to Reduce Cardiovascular Disease Risk in the Stanford and San Mateo Heart to Heart Randomised Control Trial: Study Protocol and Baseline Characteristics.
    Implement Sci. 2006 Sep 27;1(1):21 [Epub ahead of print]

  8. Manuel Fernandez-Real J, Botas-Cervero P, Lainez B, Ricart W, Delgado E.
    An alternatively spliced soluble TNF-alpha receptor is associated with metabolic disorders A replication study.
    Clin Immunol. 2006 Sep 14; [Epub ahead of print]

  9. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, Tracy RP, Savage PJ, Jackson SA.
    Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.
    J Am Geriatr Soc. 2006 Sep;54(9):1317-24.

  10. Shetty S, Eckhardt ER, Post SR, van der Westhuyzen DR.
    Phosphatidylinositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes.
    Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2125-31. Epub 2006 Jun 22.

back to top

Diabetes

  1. Ahmed I, Goldstein BJ.
    Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Mt Sinai J Med. 2006 Sep;73(5):759-68.

  2. Andre P, Balkau B, Born C, Charles MA, Eschwege E; D.E.S.I.R. study group.
    Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort.
    Diabetologia. 2006 Sep 13; [Epub ahead of print]

  3. Choo KE, Lau KB, Davis WA, Chew PH, Jenkins AJ, Davis TM.
    Cardiovascular risk factors in pre-pubertal Malays: Effects of diabetic parentage.
    Diabetes Res Clin Pract. 2006 Sep 14; [Epub ahead of print]

  4. Dayspring T, Pokrywka G.
    Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
    Curr Atheroscler Rep. 2006 Sep;8(5):356-64.

  5. Fievet C, Fruchart JC, Staels B.
    PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Curr Opin Pharmacol. 2006 Sep 12; [Epub ahead of print]

  6. Foucan L, Deloumeaux J, Donnet J, Bangou J, Larifla L, Messerchmitt C, Salmi L, Kangambega P.
    Metabolic Syndrome components in Indian migrants with type 2 diabetes. A matched comparative study.
    Diabetes Metab. 2006 Sep;32(4):337-42.

  7. Lo JC, Zhao X, Scuteri A, Brockwell S, Sowers MR.
    The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife.
    Am J Med. 2006 Sep;119(9 Suppl 1):S69-78.

  8. Matteucci E, Rosada J, Pinelli M, Giusti C, Giampietro O.
    Systolic blood pressure response to exercise in type 1 diabetes families compared with healthy control individuals.
    J Hypertens. 2006 Sep;24(9):1745-51.

  9. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V.
    Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians-Result of Indian diabetes prevention programme.
    Diabetes Res Clin Pract. 2006 Sep 16; [Epub ahead of print]

  10. Sanders BH, Lubsch LM, West DS.
    Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
    Ann Pharmacother. 2006 Sep;40(9):1517-21. Epub 2006 Aug 8.

  11. Shim WS, Kim HJ, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS.
    The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients.
    Diabetes Res Clin Pract. 2006 Sep;73(3):284-91. Epub 2006 Mar 24.

  12. Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Cardiovasc Diabetol. 2006 Sep 26;5(1):20 [Epub ahead of print]

  13. Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, Ota S, Taniai K, Hida K, Yamakado M, Shikata K, Uehara Y, Urade Y, Makino H.
    Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients.
    Diabetes Res Clin Pract. 2006 Sep 26; [Epub ahead of print]

back to top

Diet

  1. Chan YM, Varady KA, Lin Y, Trautwein E, Mensink RP, Plat J, Jones PJ.
    Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease.
    Nutr Rev. 2006 Sep;64(9):385-402.

  2. Damiao R, Castro TG, Cardoso MA, Gimeno SG, Ferreira SR, For The Japanese-Brazilian DS.
    Dietary intakes associated with metabolic syndrome in a cohort of Japanese ancestry.
    Br J Nutr. 2006 Sep;96(3):532-8.

  3. Densmore VS, Morton NM, Mullins JJ, Seckl JR.
    11 beta-hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: A novel constraint to hyperphagia?
    Endocrinology. 2006 Sep;147(9):4486-95. Epub 2006 Jun 8.

  4. Fisler JS, Warden CH.
    Uncoupling proteins, dietary fat and the metabolic syndrome.
    Nutr Metab (Lond). 2006 Sep 12;3(1):38 [Epub ahead of print]

  5. Garcia AL, Otto B, Reich SC, Weickert MO, Steiniger J, Machowetz A, Rudovich NN, Mohlig M, Katz N, Speth M, Meuser F, Doerfer J, Zunft HJ, Pfeiffer AH, Koebnick C.
    Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance.
    Eur J Clin Nutr. 2006 Sep 20; [Epub ahead of print]

  6. Griel AE, Ruder EH, Kris-Etherton PM.
    The changing roles of dietary carbohydrates: from simple to complex.
    Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):1958-65. Epub 2006 Jun 22. Review.

  7. Hirabara SM, Silveira LR, Abdulkader F, Carvalho CR, Procopio J, Curi R.
    Time-dependent effects of fatty acids on skeletal muscle metabolism.
    J Cell Physiol. 2006 Sep 29; [Epub ahead of print]

  8. Robitaille J, Gaudet D, Perusse L, Vohl MC.
    Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians.
    Int J Obes (Lond). 2006 Sep 5; [Epub ahead of print]

  9. Taneja SK, Mandal R, Girhotra S.
    Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet.
    Indian J Exp Biol. 2006 Sep;44(9):705-18.

  10. Watts GF, Chan DC, Ooi EM, Nestel PJ, Beilin LJ, Barrett PH.
    Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
    Clin Exp Pharmacol Physiol. 2006 Sep;33(9):877-82.

back to top

Drug Therapy

  1. Bodles AM, Varma V, Yao-Borengasser A, Phanavanh B, Peterson CA, McGehee RE Jr, Rasouli N, Wabitsch M, Kern PA.
    Pioglitazone induces apoptosis of macrophages in human adipose tissue.
    J Lipid Res. 2006 Sep;47(9):2080-8. Epub 2006 Jun 23.

  2. Clearfield M.
    Statins and the primary preventionof cardiovascular events.
    Curr Atheroscler Rep. 2006 Sep;8(5):390-6.

  3. Devaraj S, Chan E, Jialal I.
    DIRECT DEMONSTRATION OF AN ANTI-INFLAMMATORY EFFECT OF SIMVASTATIN IN SUBJECTS WITH THE METABOLIC SYNDROME.
    J Clin Endocrinol Metab. 2006 Sep 12; [Epub ahead of print]

  4. Haupt DW.
    Differential metabolic effects of antipsychotic treatments.
    Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S149-55. Epub 2006 Jul 25.

  5. Segura J, Ruilope LM.
    Antihypertensive therapy in patients with metabolic syndrome.
    Curr Opin Nephrol Hypertens. 2006 Sep;15(5):493-7.

  6. Siavash Dastjerdi M, Kazemi F, Najafian A, Mohammady M, Aminorroaya A, Amini M.
    An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Int J Obes (Lond). 2006 Sep 12; [Epub ahead of print]

  7. Tobin JF, Freedman LP.
    Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy.
    Trends Endocrinol Metab. 2006 Sep;17(7):284-90. Epub 2006 Jul 25.

  8. Watts GF, Ji J, Chan DC, Ooi EM, Johnson AG, Rye KA, Barrett PH.
    Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
    Clin Sci (Lond). 2006 Sep;111(3):193-9.

  9. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, Oral ET, Atagun I.
    Atypical antipsychotics related metabolic syndrome in bipolar patients.
    J Affect Disord. 2006 Sep 11; [Epub ahead of print]

back to top

Epidemiology

  1. The DECODA Study Group.
    Prevalence of the metabolic syndrome in populations of Asian origin Comparison of the IDF definition with the NCEP definition.
    Diabetes Res Clin Pract. 2006 Sep 26; [Epub ahead of print]

  2. Florez H, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Castillo-Florez S, Lee D, Goldberg R.
    Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population.
    Atherosclerosis. 2006 Sep;188(1):134-41. Epub 2005 Nov 18.

  3. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C.
    Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey).
    J Acquir Immune Defic Syndr. 2006 Sep 14; [Epub ahead of print]

  4. Heldgaard PE, Griffin SJ.
    Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome.
    Diabet Med. 2006 Sep;23(9):996-1002.

  5. Lao XQ, Thomas GN, Jiang CQ, Zhang WS, Yin P, Adab P, Lam TH, Cheng KK.
    c-Reactive protein and the metabolic syndrome in older Chinese: Guangzhou Biobank Cohort Study.
    Atherosclerosis. 2006 Sep 27; [Epub ahead of print]

  6. Miyatake N, Wada J, Kawasaki Y, Matsumoto S, Makino H, Numata T.
    Relationship between metabolic syndrome and proteinuria in the Japanese population.
    Intern Med. 2006 Sep;45(9):599-603. Epub 2006 Jun 1.

  7. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, Hirakata H, Iida M.
    Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study.
    Am J Kidney Dis. 2006 Sep;48(3):383-91.

  8. Roriz-Cruz M, Rosset I, Wada T, Sakagami T, Ishine M, De Sa Roriz-Filho J, Cruz TR, Hosseinkhani M, Rodrigues RP, Sudoh S, Arai H, Wakatsuki Y, Souza AC, Nakagawa M, Kita T, Matsubayashi K.
    Cognitive impairment and frontal-subcortical geriatric syndrome are associated with metabolic syndrome in a stroke-free population.
    Neurobiol Aging. 2006 Sep 6; [Epub ahead of print]

  9. Stejskal D, Karpisek M.
    Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?
    Eur J Clin Invest. 2006 Sep;36(9):621-5.

  10. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J.
    Association of metabolic syndrome with Alzheimer disease: a population-based study.
    Neurology. 2006 Sep 12;67(5):843-7.

  11. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R.
    Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures.
    Liver Int. 2006 Sep;26(7):856-63.

  12. Zhang L, Pu K, Zhang SY, Ren WQ.
    Blood rheological properties are strongly related to the metabolic syndrome in middle-aged Chinese.
    Int J Cardiol. 2006 Sep 20;112(2):229-33. Epub 2006 Apr 27.

back to top

Exercise

  1. Platat C, Wagner A, Klumpp T, Schweitzer B, Simon C.
    Relationships of physical activity with metabolic syndrome features and low-grade inflammation in adolescents.
    Diabetologia. 2006 Sep;49(9):2078-2085. Epub 2006 Jun 22

  2. Zhang JQ, Ji LL, Fretwell VS, Nunez G.
    Effect of exercise on postprandial lipemia in men with hypertriglyceridemia.
    Eur J Appl Physiol. 2006 Sep 28; [Epub ahead of print]

back to top

Genetics

  1. Corella D.
    Gene-alcohol interactions in the metabolic syndrome.
    Nutr Metab Cardiovasc Dis. 2006 Sep 25; [Epub ahead of print]

  2. Eichers ER, Abd-El-Barr MM, Paylor R, Lewis RA, Bi W, Lin X, Meehan TP, Stockton DW, Wu SM, Lindsay E, Justice MJ, Beales PL, Katsanis N, Lupski JR.
    Phenotypic characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity.
    Hum Genet. 2006 Sep;120(2):211-26. Epub 2006 Jun 23.

  3. Gout J, Tirard J, Thevenon C, Riou JP, Begeot M, Naville D.
    CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11beta-hydroxysteroid dehydrogenase encoding gene in adipose cells.
    Biochimie. 2006 Sep;88(9):1115-24. Epub 2006 Jul 5.

  4. Kang ES, Nam M, Kim HJ, Kim HJ, Myoung SM, Rhee Y, Ahn CW, Cha BS, Lee HC.
    Haplotype combination of Calpain-10 gene polymorphism is associated with metabolic syndrome in type 2 diabetes.
    Diabetes Res Clin Pract. 2006 Sep;73(3):268-75. Epub 2006 Mar 20.

  5. Pollex RL, Hegele RA.
    Genetic determinants of the metabolic syndrome.
    Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):482-9.

  6. Tchkonia T, Lenburg M, Thomou T, Giorgadze N, Frampton G, Pirtskhalava T, Cartwright A, Cartwright M, Flanagan J, Karagiannides I, Gerry N, Forse RA, Tchoukalova Y, Jensen MD, Pothoulakis C, Kirkland JL.
    Identification of Depot-Specific Human Fat Cell Progenitors through Distinct Expression Profiles and Developmental Gene Patterns.
    Am J Physiol Endocrinol Metab. 2006 Sep 19; [Epub ahead of print]

  7. Vimaleswaran KS, Radha V, Mohan V.
    Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians.
    Metabolism. 2006 Sep;55(9):1222-6.

back to top

HDL-cholesterol

  1. Chapman MJ.
    Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Pharmacol Ther. 2006 Sep;111(3):893-908. Epub 2006 Mar 29.

  2. Dekroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ.
    APOE4-VLDL Inhibits the HDL-Activated Phosphatidylinositol 3-Kinase/Akt Pathway via the Phosphoinositol Phosphatase SHIP2.
    Circ Res. 2006 Sep 14; [Epub ahead of print]

  3. Kontush A, Chapman MJ.
    Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Pharmacol Rev. 2006 Sep;58(3):342-74.

back to top

Hypertension

  1. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E,
    Boger RH.
    Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
    Metabolism. 2006 Sep;55(9):1159-64.

  2. Ishizaka N, Ishizaka Y, Hashimoto H, Toda E, Nagai R, Yamakado M.
    Metabolic syndrome may not associate with carotid plaque in subjects with optimal, normal, or high-normal blood pressure.
    Hypertension. 2006 Sep;48(3):411-7. Epub 2006 Jul 31.

  3. Tartan Z, Uyarel H, Kasikcioglu H, Alper AT, Ozay B, Bilsel T, Gul M, Ozturk R, Cam N.
    Metabolic syndrome as a predictor of non-dipping hypertension.
    Tohoku J Exp Med. 2006 Sep;210(1):57-66.

back to top

Insulin Sensitivity

  1. Fosgerau K, Fledelius C, Pedersen KE, Kristensen JB, Daugaard JR, Iglesias MA, Kraegen EW, Furler SM.
    Oral administration of glucose promotes intracellular partitioning of fatty acid toward storage in white but not in red muscle.
    J Endocrinol. 2006 Sep;190(3):651-8.

  2. Matsumoto M, Han S, Kitamura T, Accili D.
    Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.
    J Clin Invest. 2006 Sep;116(9):2464-72. Epub 2006 Aug 10.

  3. Yamada T, Ozaki N, Kato Y, Miura Y, Oiso Y.
    Insulin downregulates angiopoietin-like protein 4 mRNA in 3T3-L1 adipocytes.
    Biochem Biophys Res Commun. 2006 Sep 8;347(4):1138-44. Epub 2006 Jul 17

back to top

Lipoproteins

  1. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.
    Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
    Lancet. 2006 Sep 9;368(9539):919-28.

  2. Dugue-Pujol S, Rousset X, Pastier D, Tran Quang N, Pautre V, Chambaz J, Chabert M, Kalopissis AD.
    Human apolipoprotein A-II induces hypertriglyceridemia in transgenic mice by associating with triglyceride-rich lipoproteins in plasma and impairing their catabolism.
    J Lipid Res. 2006 Sep 21; [Epub ahead of print]

  3. Handberg A, Levin K, Hojlund K, Beck-Nielsen H.
    Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance.
    Circulation. 2006 Sep 12;114(11):1169-76. Epub 2006 Sep 4.

  4. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K.
    Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.
    Diabetes Res Clin Pract. 2006 Sep 4; [Epub ahead of print]

back to top

Nitric Oxide

  1. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G.
    Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates.
    J Nutr Biochem. 2006 Sep;17(9):571-88. Epub 2006 Jan 9.

  2. Unno Y, Akuta T, Sakamoto Y, Horiuchi S, Akaike T.
    Nitric oxide-induced downregulation of leptin production by 3T3-L1 adipocytes.
    Nitric Oxide. 2006 Sep;15(2):125-32. Epub 2006 Jan 25.

back to top

Non-Alcoholic Fatty Liver Disease

  1. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I.
    Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.
    Liver Int. 2006 Sep;26(7):864-71.

  2. Machado M, Cortez-Pinto H.
    Non-alcoholic steatohepatitis and metabolic syndrome.
    Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):637-42.

  3. Ono M, Saibara T.
    Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature.
    J Gastroenterol. 2006 Sep;41(8):725-32.

  4. Roberts EA, Yap J.
    Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient.
    Curr Treat Options Gastroenterol. 2006 Sep;9(5):423-31

  5. Targher G, Arcaro G.
    Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
    Atherosclerosis. 2006 Sep 11; [Epub ahead of print]

  6. Weinberg JM.
    Lipotoxicity.
    Kidney Int. 2006 Sep 6; [Epub ahead of print]

  7. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL.
    Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.
    Clin Gastroenterol Hepatol. 2006 Sep;4(9):1154-61. Epub 2006 Aug 14.

back to top

Obesity

  1. Burke V.
    Obesity in childhood and cardiovascular risk.
    Clin Exp Pharmacol Physiol. 2006 Sep;33(9):831-7.

  2. Fezeu L, Balkau B, Kengne AP, Sobngwi E, Mbanya JC.
    Metabolic syndrome in a sub-Saharan African setting: Central obesity may be the key determinant.
    Atherosclerosis. 2006 Sep 29; [Epub ahead of print]

  3. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, Chade AR, Lerman LO, Lerman A.
    EARLY EXPERIMENTAL OBESITY IS ASSOCIATED WITH CORONARY ENDOTHELIAL DYSFUNCTION AND OXIDATIVE STRESS.
    Am J Physiol Heart Circ Physiol. 2006 Sep 29; [Epub ahead of print]

  4. Ismail-Beigi F, Catalano PM, Hanson RW.
    Metabolic programming: fetal origins of obesity and metabolic syndrome in the adult.
    Am J Physiol Endocrinol Metab. 2006 Sep;291(3):E439-40. Epub 2006 Apr 25. Review.

  5. Kawai T, Ito T, Ohwada K, Mera Y, Matsushita M, Tomoike H.
    Hereditary Postprandial Hypertriglyceridemic Rabbit Exhibits Insulin Resistance and Central Obesity. A Novel Model of Metabolic Syndrome.
    Arterioscler Thromb Vasc Biol. 2006 Sep 21; [Epub ahead of print]

  6. Molavi B, Rasouli N, Kern PA.
    The prevention and treatment of metabolic syndrome and high-risk obesity.
    Curr Opin Cardiol. 2006 Sep;21(5):479-85.

  7. Omouessi ST, Chapleur M, Leshem M, Thornton SN.
    Gender and obesity influence sodium intake and fluid regulation in Zucker rats following repeated sodium depletions.
    Physiol Behav. 2006 Sep 4; [Epub ahead of print]

  8. Ryan MJ, McLemore Jr GR, Hendrix ST.
    Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus.
    Hypertension. 2006 Sep 18; [Epub ahead of print]

  9. See CQ, Mensah E, Olopade CO.
    Obesity, ethnicity, and sleep-disordered breathing: medical and health policy implications.
    Clin Chest Med. 2006 Sep;27(3):521-33, viii.

  10. Song D, Hutchings SR, Pang CC.
    Impaired in vivo venous constriction in conscious obese Zucker rats with metabolic syndrome.
    Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):451-6. Epub 2006 Aug 31

  11. Yang YC, Wu JS, Lu FH, Chang WC, Wu CH, Chang CJ.
    In addition to obesity and insulin resistance, microalbuminuria and diminished insulin secretion are linked with the metabolic syndrome in community-dwelling nondiabetic Taiwanese subjects.
    Diabetes Res Clin Pract. 2006 Sep 4; [Epub ahead of print]

back to top

Psychological Aspects

  1. Van Gaal LF.
    Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity.
    Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S142-8. Epub 2006 Jul 24.

  2. De Hert M, Peuskens B, van Winkel R, Kalnicka D, Hanssens L, Van Eyck D, Wyckaert S, Peuskens J.
    Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE(R).
    Schizophr Res. 2006 Sep 20; [Epub ahead of print]

  3. Buijs RM, Kreier F.
    The metabolic syndrome: a brain disease?
    J Neuroendocrinol. 2006 Sep;18(9):715-6. Review.

  4. Yancura LA, Aldwin CM, Levenson MR, Spiro A 3rd.
    Coping, affect, and the metabolic syndrome in older men: how does coping get under the skin?
    J Gerontol B Psychol Sci Soc Sci. 2006 Sep;61(5):P295-303.

back to top

PCOS / Menopause / Metabolic Syndrome in Women

  1. Barden A.
    Pre-eclampsia: contribution of maternal constitutional factors and the consequences for cardiovascular health.
    Clin Exp Pharmacol Physiol. 2006 Sep;33(9):826-30.

  2. Chen MJ, Yang WS, Yang JH, Hsiao CK, Yang YS, Ho HN.
    Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.
    Hum Reprod. 2006 Sep;21(9):2266-71. Epub 2006 Jun 6.

  3. ESHRE Capri Workshop Group.
    Hormones and cardiovascular health in women.
    Hum Reprod Update. 2006 Sep-Oct;12(5):483-97. Epub 2006 Jun 28

  4. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, Lees RS, Lee H, Grinspoon S.
    Carotid Intimal Medial Thickness in HIV Infected Women: Effects of Protease Inhibitor Use, Cardiac Risk Factors and the Metabolic Syndrome.
    J Clin Endocrinol Metab. 2006 Sep 26; [Epub ahead of print]

  5. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, Ble A, Egan JM, Metter EJ, Abbatecola AM, Zuliani G, Ruggiero C, Valenti G, Guralnik JM, Ferrucci L.
    Association of Hormonal Dysregulation with Metabolic Syndrome in Older Women (Data from the InCHIANTI Study).
    Am J Physiol Endocrinol Metab. 2006 Sep 12; [Epub ahead of print]

  6. Nestel P.
    Relationship between arterial stiffness and glucose metabolism in women with metabolic syndrome.
    Clin Exp Pharmacol Physiol. 2006 Sep;33(9):883-6.

  7. Okobia MN, Bunker CH, Zmuda JM, Osime U, Ezeome ER, Anyanwu SN, Uche EE, Ojukwu J, Kuller LH.
    Anthropometry and breast cancer risk in nigerian women.
    Breast J. 2006 Sep-Oct;12(5):462-6.

  8. Rosano GM, Vitale C, Tulli A.
    Managing cardiovascular risk in menopausal women.
    Climacteric. 2006 Sep;9(5):19-2

  9. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE.
    Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.
    Diabetes Obes Metab. 2006 Sep;8(5):538-54.

  10. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia SR.
    Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN).
    Am J Med. 2006 Sep;119(9 Suppl 1):S103-10.

    back to top

Pediatrics

  1. Fu JF, Liang L, Zou CC, Hong F, Wang CL, Wang XM, Zhao ZY.
    Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.
    Int J Obes (Lond). 2006 Sep 5; [Epub ahead of print]

  2. Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, Youngren NM, Glasser SP, Baker KS.
    Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2006 Sep 15;107(6):1303-12.

  3. Koklu E, Akcakus M, Kurtoglu S, Koklu S, Yikilmaz A, Coskun A, Gunes T.
    Aortic intima-media thickness and lipid profile in macrosomic newborns.
    Eur J Pediatr. 2006 Sep 15; [Epub ahead of print]

  4. Singh GK.
    Metabolic Syndrome in Children and Adolescents.
    Curr Treat Options Cardiovasc Med. 2006 Sep;8(5):403-413.

back to top

Renal Function

  1. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M.
    Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.
    Nephrol Dial Transplant. 2006 Sep 23; [Epub ahead of print]

  2. Finkelstein J, Joshi A, Hise MK.
    Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III).
    Am J Kidney Dis. 2006 Sep;48(3):372-82.

back to top

Risk Factors

  1. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, Crowther M, Venco A.
    The metabolic syndrome and the risk of venous thrombosis: a case-control study.
    J Thromb Haemost. 2006 Sep;4(9):1914-8. Epub 2006 Jul 17.

  2. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT.
    Metabolic syndrome as a risk factor for coronary heart disease and stroke: An 11-year prospective cohort in Taiwan community.
    Atherosclerosis. 2006 Sep 13; [Epub ahead of print]

  3. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, Balercia G, Chiarini V, Forti G, Maggi M.
    Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction.
    Eur Urol. 2006 Sep;50(3):595-604; discussion 604. Epub 2006 Mar 13.

  4. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A.
    Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk.
    Eur Heart J. 2006 Sep;27(18):2247-55. Epub 2006 Aug 15.

  5. Forouhi NG, Sattar N, Tillin T, McKeigue PM, Chaturvedi N.
    Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK.
    Diabetologia. 2006 Sep 14; [Epub ahead of print]

  6. Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL.
    Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome.
    Heart. 2006 Sep 4; [Epub ahead of print]

  7. Meshkani R, Taghikhani M, Larijani B, Khatami S, Khoshbin E, Adeli K.
    The relationship between homeostasis model assessment and cardiovascular risk factors in Iranian subjects with normal fasting glucose and normal glucose tolerance.
    Clin Chim Acta. 2006 Sep;371(1-2):169-75. Epub 2006 May 22.

  8. Sebekova K, Boor P, Valachovicova M, Blazicek P, Parrak V, Babinska K, Heidland A, Krajcovicova-Kudlackova M.
    Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians.
    Mol Nutr Food Res. 2006 Sep;50(9):858-68.

  9. Tande AJ, Platz EA, Folsom AR.
    The Metabolic Syndrome Is Associated with Reduced Risk of Prostate Cancer.
    Am J Epidemiol. 2006 Sep 12; [Epub ahead of print]

  10. Tangalos EG, Cota D, Fujioka K.
    Complex cardiometabolic risk factors: impact, assessment, and emerging therapies.
    J Am Med Dir Assoc. 2006 Sep;7(7 Suppl):1-10.

  11. Yilmaz MB, Guray Y, Guray U, Biyikoglu SF, Tandogan I, Korkmaz S.
    Metabolic syndrome increases the risk of significant coronary artery involvement in patients with peripheral artery disease.
    Coron Artery Dis. 2006 Sep;17(6):529-32.

Treatment

  1. Kasuga JI, Yamasaki D, Araya Y, Nakagawa A, Makishima M, Doi T, Hashimoto Y, Miyachi H.
    Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Bioorg Med Chem. 2006 Sep 21; [Epub ahead of print]

  2. Oben J, Kuate D, Agbor G, Momo C, Talla X.
    The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome.
    Lipids Health Dis. 2006 Sep 2;5:24.

  3. Richards S, Sorensen B, Jae HS, Winn M, Chen Y, Wang J, Fung S, Monzon K, Frevert EU, Jacobson P, Sham H, Link JT.
    Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
    Bioorg Med Chem Lett. 2006 Sep 23; [Epub ahead of print]

  4. van Zwieten PA, Mancia G.
    Background and treatment of metabolic syndrome: a therapeutic challenge.
    Semin Cardiothorac Vasc Anesth. 2006 Sep;10(3):206-14.

Coordinated by Dr. Scott Grundy, President of the IAS